Post by Vesiculab

Enhancing anti-tumor efficacy with TLD, an optimized liposomal doxorubicin formulation with small vesicle size: in their latest article, Sime Brkic, Stefan Halbherr, Camille F. Peitsch at InnoMedica Holding AG and collaborators consolidated a decade of preclinical research on Talidox (TLD), combining physicochemical characterization with in vitro and in vivo efficacy studies. TLD, an optimized liposomal doxorubicin formulation, was designed to enhance drug delivery efficiency and reduce systemic toxicity compared to existing formulations. With its smaller particle size and optimized drug-to-lipid ratio relative to Caelyx, TLD achieved improved tumor penetration, uptake, and therapeutic efficacy. Preclinical studies in breast cancer and soft tissue sarcoma models demonstrated superior efficacy of TLD over free doxorubicin while maintaining a strong safety profile, complementing previously published clinical findings that showed a favorable risk–benefit ratio 🔗 https://lnkd.in/e5nVPVRt Despite chemical and size differences between TLD and Caelyx, both formulations were morphologically similar in circularity, lamellarity, and liposome loading percentage. In a breast cancer mouse model, TLD and Caelyx achieved comparable tumor reduction, both outperforming free doxorubicin. However, in a soft tissue sarcoma model, TLD showed superior tumor shrinkage and survival benefit over both Caelyx and free doxorubicin. Taken together, the preclinical data on tumor reduction and survival outcomes strongly supported the clinical promise of TLD. Clinical trials have already begun, with early results reported. An article co-authored by Silvia Erni, Younes Louaguenouni, Marianna Carone, E. Henrik Peters, Andreas Schreiber, Andreas Zumbuehl and Alberto Gabizon. #nanomedicine #liposomes #doxorubicin #breastcancer #Vesiculab